Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 2:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Increase Protein Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Antecedent Metabolic Health and Metformin Aging Study

NCT04264897
View directory record Official record
Conditions
Aging, Insulin Sensitivity, Chronic Disease, Mitochondria, Insulin Resistance
Interventions
Metformin, Placebo oral tablet
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
40 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 16, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
View directory record Official record
Conditions
Sarcoma, Alveolar Soft Part
Interventions
Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 16, 2026, 2:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3

NCT00685945
View directory record Official record
Conditions
Obesity
Interventions
Control (bradykinin), L-NMMA + bradykinin, Isosorbide + L-NMMA + bradykinin, Sildenafil + L-NMMA + bradykinin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Sep 16, 2026, 2:06 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

NCT04671966
View directory record Official record
Conditions
Heart Diseases, Left Ventricular Dysfunction
Interventions
Estradiol patch, Cetrotide, Fasting, Lower Body Negative Pressure
Drug · Other
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 30 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 16, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients

NCT00459056
View directory record Official record
Conditions
Abdominal Obesity, Hypertension
Interventions
Carvedilol CR + Lisinopril, Lisinopril + HCTZ
Drug
Lead sponsor
St. Paul Heart Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Sep 16, 2026, 2:06 PM EDT
Completed Not applicable Interventional

Misoprostol With Mechanical Dilation Versus Oxytocin With Mechanical Dilation for High-risk Pregnancy Inductions

NCT04492072
View directory record Official record
Conditions
Cesarean Section, Misoprostol, Oxytocin, High Risk Pregnancy
Interventions
Oxytocin, Misoprostol
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 16, 2026, 2:06 PM EDT
Withdrawn Phase 2 Interventional

A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel

NCT00768131
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions
Cetuximab, Paclitaxel, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
14
States / cities
Little Rock, Arkansas • Long Beach, California • Boynton Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Sep 16, 2026, 2:06 PM EDT
Terminated No phase listed Observational

Vascular Dysfunction in Diabetes: Genes and Hormones

NCT01511042
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Para-aminohippuric Acid, Angiotensin II, Norepinephrine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Sep 16, 2026, 2:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of High Protein Weight Loss for Seniors

NCT02730988
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Weight Stable Group
Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
65 Years to 79 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 16, 2026, 2:06 PM EDT
Completed Not applicable Interventional

UC Cohort - The Influence of Diet on Gut Microbiotas

NCT04933162
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
High Protein and Low Fiber Diet, Low Protein and High Fiber Diet
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 16, 2026, 2:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes

NCT00678080
View directory record Official record
Conditions
Pregnancy Complications
Interventions
Metformin, Insulin (NPH and Regular)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
Brownsville, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Sep 16, 2026, 2:06 PM EDT
Completed Phase 1Phase 2 Interventional

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

NCT01931046
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
Ad5-SGE-REIC/Dkk3
Drug
Lead sponsor
Momotaro-Gene Inc.
Industry
Eligibility
50 Years to 80 Years · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
3
States / cities
San Diego, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Sep 16, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy

NCT02607254
View directory record Official record
Conditions
Idiopathic Small Fiber Neuropathy
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Sep 16, 2026, 2:06 PM EDT
Active, not recruiting Phase 1 Interventional

Caveolin-1 and Vascular Dysfunction

NCT01426529
View directory record Official record
Conditions
Hypertension, Insulin Resistance
Interventions
Para-aminohippuric Acid, Angiotensin II, Norepinephrine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 16, 2026, 2:06 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

NCT06732401
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Echocardiography Test
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
192
States / cities
Jonesboro, Arkansas • Beverly Hills, California • Los Angeles, California + 163 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 16, 2026, 2:06 PM EDT
Completed Phase 3 Interventional Results available

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

NCT04938830
View directory record Official record
Conditions
RSV Infection
Interventions
Clesrovimab, Palivizumab, Placebo
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 1 Year
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
29
States / cities
Long Beach, California • Orange, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 16, 2026, 2:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pitocin or Oral Misoprostol for PROM IOL

NCT04028765
View directory record Official record
Conditions
PROM
Interventions
Misoprostol, Oxytocin
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 16, 2026, 2:06 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Animal and Plant Proteins and Glucose Metabolism

NCT03994367
View directory record Official record
Conditions
Metabolic Syndrome, Metabolic Syndrome, Protection Against, Glucose Metabolism Disorders
Interventions
High animal protein isolate, High animal protein whole food, High plant protein isolate, High plant protein whole food
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 16, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT01234467
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Lymphoma, Diffuse Large-Cell, Diffuse Large-Cell Lymphoma, Lymphoma
Interventions
Bendamustine, Rituximab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Boone, North Carolina • Chapel Hill, North Carolina • Concord, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Sep 16, 2026, 2:06 PM EDT
Withdrawn Early Phase 1 Interventional

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

NCT03554707
View directory record Official record
Conditions
Childhood CNS Tumor
Interventions
SGT-53, Radiation, Irinotecan, Temozolomide, Bevacizumab
Genetic · Radiation · Drug
Lead sponsor
SynerGene Therapeutics, Inc.
Industry
Eligibility
1 Year to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 16, 2026, 2:06 PM EDT
Not listed Phase 1Phase 2 Interventional

ASIS for Botox in Upper Limb Spasticity

NCT02074150
View directory record Official record
Conditions
Upper Limb Spasticity Unilaterally in Adults With History of Stroke, Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
Interventions
Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12,, Efficacy of Botox intramuscularly at Week 18, Efficacy of Botox intramuscularly at Week 24, Efficacy of Botox intramuscularly at Week 30, Efficacy of Botox subdermally at Week 6, Efficacy of Botox subdermally at Week 12, Efficacy of Botox subdermally at Week 18, Efficacy of Botox subdermally at Week 24, Efficacy of Botox subdermally at Week 30, Adverse Reactions of Botox intramuscularly, Adverse Reactions of Botox subdermally
Drug
Lead sponsor
li nguyen
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Sep 16, 2026, 2:06 PM EDT
Completed Phase 1 Interventional

CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors

NCT00819806
View directory record Official record
Conditions
NY-ESO-1-expressing Tumors
Interventions
Vaccine only, Vaccine + cyclophosphamide
Biological
Lead sponsor
Hassane M. Zarour, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 16, 2026, 2:06 PM EDT
Completed Not applicable Interventional Results available

Piloting a Family-Based Intervention of Time-Restricted Eating to Treat Obesity

NCT05107726
View directory record Official record
Conditions
Childhood Obesity
Interventions
TRE Group
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
3 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 16, 2026, 2:06 PM EDT
Completed Phase 1 Interventional

Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas

NCT03036904
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions
Venetoclax, Rituximab, Etoposide, Vincristine Sulfate, Cyclophosphamide, Prednisone, Doxorubicin Hydrochloride
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Sep 16, 2026, 2:06 PM EDT